Finance

Lists
Why is FHTX up 9.09%?
Dive Deeper
FHTX:NASDAQ
Foghorn Therapeutics Inc
$2.04
+9.09%
(+0.17) 1D
$2.04
0.00% (0.00)
Pre-market
Closed: Nov 9, 4:00:00 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for FHTX...
Open
$2.08
High
$2.12
Low
$1.89
Mkt. cap
121.15M
Avg. vol.
1.17M
Volume
808.00
52-wk high
$7.61
52-wk low
$1.79
EPS
-$0.98
Beta
3.22
Shares outstanding
59.38M
No. of employees
106
Open
$2.08
High
$2.12
Low
$1.89
Mkt. cap
121.15M
Avg. vol.
1.17M
Volume
808.00
52-wk high
$7.61
52-wk low
$1.79
EPS
-$0.98
Beta
3.22
Shares outstanding
59.38M
No. of employees
106
News stories
From web sources and news partners
About Foghorn Therapeutics Inc
CEO-
Employees106
Founded2015
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websitefoghorntx.com
Analyst ratings
Based on 9 analysts giving stock ratings to FHTX in the past 3 months
Buy
Buy
4
Hold
5
Sell
0
12-month forecast
Based on 9 Wall Street analysts offering 12 month price targets for FHTX in the last 3 months.
Highest
Current $2.04
$10.00 (+390.20%)
Average
$5.00 (+145.10%)
Lowest
$2.00 (-1.96%)
Analyst
Recommendation
Action
Price target
Projected
Date
Jeet Mukherjee
BTIG
Hold
Maintained
-
-
11/09/2026
Andrew Fein
H.C. Wainwright
Buy
Reiterated
$5.00
+145.1%
11/10/2026
Unknown Analyst
Guggenheim
Buy
Maintained
$5.00
+145.1%
11/09/2026
Gavin Clark-Gartner
Evercore ISI
Hold
Downgraded
$3.00
+47.1%
10/13/2026
Robert Driscoll
Wedbush
Hold
Downgraded
$2.00
-2%
10/02/2026
Andres Y. Maldonado
H.C. Wainwright
Buy
Reiterated
$5.00
+145.1%
10/02/2026
Yaron Werber
TD Cowen
Hold
Downgraded
-
-
10/01/2026
Silvan Tuerkcan
Citizens JMP
Hold
Downgraded
-
-
10/01/2026
Laura Prendergast
Stifel Nicolaus
Buy
Maintained
$5.00
+145.1%
10/01/2026
Unknown Analyst
B. Riley Securities
Buy
Initiated
$10.00
+390.2%
08/27/2026
Unknown Analyst
Evercore ISI
Buy
Maintained
$14.00
+586.3%
08/10/2026
Michael Schmidt
Guggenheim
Buy
Maintained
$12.00
+488.2%
03/11/2026
Amin Makarem
Jefferies
Buy
Maintained
$12.00
+488.2%
02/16/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
8.15M
9.25M
3.27M
16.07M
Cost of goods sold
20.00M
22.05M
18.26M
18.52M
Cost of revenue
20.00M
22.05M
18.26M
18.52M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
6.65M
6.80M
6.58M
6.35M
Operating expense
6.65M
6.80M
6.58M
6.35M
Total operating expenses
26.65M
28.84M
24.84M
24.88M
Operating income
-18.50M
-19.60M
-21.57M
-8.80M
Other non operating income
620.00K
502.00K
-44.00K
5.00K
EBT including unusual items
-15.85M
-21.66M
-19.88M
-7.19M
EBT excluding unusual items
-15.85M
-17.38M
-19.88M
-7.19M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-15.85M
-21.66M
-19.88M
-7.19M
Net profit margin
-194.39%
-234.28%
-608.36%
-44.74%
Earnings per share
-0.25
-0.37
-0.29
-0.10
Interest and investment income
2.03M
1.71M
1.74M
1.61M
Interest expense
-
-
-
-
Net interest expenses
2.03M
1.71M
1.74M
1.61M
Depreciation and amortization charges
-
-
-
-
EBITDA
-17.65M
-18.79M
-21.34M
-8.58M
Gain or loss from assets sale
-
31.00K
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps